- Home
- MBWM vs PRAX Comparison
MBWM vs PRAX Comparison
Compare MBWM & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBWM
- PRAX
- Stock Information
- Founded
- MBWM 1997
- PRAX 2015
- Country
- MBWM United States
- PRAX United States
- Employees
- MBWM N/A
- PRAX 82
- Industry
- MBWM Major Banks
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- MBWM Finance
- PRAX Health Care
- Exchange
- MBWM Nasdaq
- PRAX Nasdaq
- Market Cap
- MBWM 726.9M
- PRAX 950.8M
- IPO Year
- MBWM 1997
- PRAX 2020
- Fundamental
- Price
- MBWM $49.44
- PRAX $53.60
- Analyst Decision
- MBWM Buy
- PRAX Strong Buy
- Analyst Count
- MBWM 2
- PRAX 10
- Target Price
- MBWM $52.25
- PRAX $101.00
- AVG Volume (30 Days)
- MBWM 98.7K
- PRAX 298.2K
- Earning Date
- MBWM 07-22-2025
- PRAX 08-12-2025
- Dividend Yield
- MBWM 3.02%
- PRAX N/A
- EPS Growth
- MBWM N/A
- PRAX N/A
- EPS
- MBWM 4.80
- PRAX N/A
- Revenue
- MBWM $222,296,000.00
- PRAX $8,122,000.00
- Revenue This Year
- MBWM $8.87
- PRAX N/A
- Revenue Next Year
- MBWM $3.71
- PRAX $6,358.50
- P/E Ratio
- MBWM $10.22
- PRAX N/A
- Revenue Growth
- MBWM 0.96
- PRAX 270.02
- 52 Week Low
- MBWM $37.76
- PRAX $26.70
- 52 Week High
- MBWM $52.98
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- MBWM 65.04
- PRAX 77.29
- Support Level
- MBWM $48.44
- PRAX $45.70
- Resistance Level
- MBWM $50.52
- PRAX $53.35
- Average True Range (ATR)
- MBWM 1.13
- PRAX 2.64
- MACD
- MBWM 0.22
- PRAX 0.74
- Stochastic Oscillator
- MBWM 80.95
- PRAX 99.06
About MBWM Mercantile Bank Corporation
Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.